Metagenomi Therapeutics, Inc. · Biotech

MGX

Elevated riskNext report: Around Nov 11 (est.)

View price ↗

The short version

A company still losing money with shrinking sales, with elevated risk. Institutions are trimming.

Going well

No debt reported

Watch out for

About 6 months of cash left at its current burn
Losing money, losses are large next to sales
Revenue down 51.8% from the year before

Money moves

No insider buying or selling in the last 30 days
Institutions cut 3.1% from their holdings in the quarter ending June 2026 (16 bought, 21 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$0.77-6.1% that day

Company value: $29M; Share price times all shares
Price vs sales: 1.2x; No profit over the last year, so this compares value with sales instead
Cash vs value: 134%; A big cushion: cash is a large part of what the company is worth

From MGX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

Not reported

Sep '23Tap a barJun '26

What the price assumes

Your guesses, our math

Move the sliders to your own view of MGX. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).

Sales growth-10% a yearRecently: -25% a yearProfit margin10%Not reportedP/E at the end15xMany steady companies trade at 12x to 25xShare count change0% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$15M

Profit in 5 years$1M

Price these guesses point to$0.59-23% vs $0.77 todayAbout -5.2% a year, before dividends

What today's price needs: with a 10% margin and a 15x P/E, sales could shrink about 5.1% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/4Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-44.7%
PassDebt under half of equityNot relying on borrowed money.No debt reported
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-348.5%
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$89.5M

Revenue: $25.2M; -51.8% vs prior year
Total debt: None; 0.00x equity
Current ratio: 7.22x; short-term assets / bills due
Free cash flow: -$89.5M; -354.9% of revenue

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: profitable every year, share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.